Impax Laboratories (NASDAQ: IPXL) released its earnings data on Monday. The company reported $0.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.19 by $0.11. The company had revenue of $141.10 million for the quarter, compared to the consensus estimate of $127.03 million. During the same quarter last year, the company posted $0.33 earnings per share. Impax Laboratories’s revenue was down 11.0% compared to the same quarter last year.
IPXL has been the subject of a number of recent research reports. Analysts at Leerink Swann cut their price target on shares of Impax Laboratories from $24.00 to $22.00 in a research note to investors on Tuesday, January 22nd. They now have an “outperform” rating on the stock. On the ratings front, analysts at Zacks downgraded shares of Impax Laboratories from a “neutral” rating to an “underperform” rating in a research note to investors on Thursday, January 10th. They now have a $20.80 price target on the stock. Finally, analysts at JPMorgan Chase cut their price target on shares of Impax Laboratories from $26.00 to $24.00 in a research note to investors on Friday, December 28th. They now have a “neutral” rating on the stock.
Five research analysts have rated the stock with a buy rating, seven have given a hold rating, and one has given an underweight rating to the company. The company has an average rating of “overweight” and an average price target of $23.22.
Impax Laboratories (IPXL) traded up 0.46% on Monday, hitting $19.62. Impax Laboratories (IPXL) has a 1-year low of $18.90 and a 1-year high of $27.25. The stock’s 50-day moving average is currently $20.44. The company has a market cap of $1.296 billion and a price-to-earnings ratio of 18.27.
Impax Laboratories, Inc. (Impax) is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.